Ginkgo Bioworks acquires Modulus Therapeutics’ cell therapy platform assets

Ginkgo Bioworks announced the acquisition of Modulus Therapeutics’ cell therapy platform assets, including their chimeric antigen receptor, or CAR, and switch receptor libraries. Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases. In contrast to legacy cell therapy design, the company uses a combinatorial approach to build and screen cell therapy components that work in concert with one another to yield novel cell behaviors. Modulus has used its platform to develop and screen libraries of novel NK-specific and T-cell specific CAR and switch receptor designs, which enable improved control and performance of immune cell-based therapies. Modulus’ assets complement Ginkgo’s extensive cell therapy capabilities. With this addition, Ginkgo looks forward to supporting its customers who are improving the performance of T-cell and NK-cell based CAR therapies to treat solid tumors, autoimmune, and other diseases.